About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

OFSEP High Definition Cohort | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingNCT03603457

OFSEP High Definition Cohort

For neurologists and patients, it appears that one major unmet need, beside of course a cure to multiple sclerosis (MS), is to better appreciate the causal factors of disease progression, and even to ...

Lead sponsor: EDMUS Foundation•25 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

EDMUS Foundation

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of multiple sclerosis according to the most recent criteria at entry into the HD cohort
•Followed in one MS Clinical Reference Centre (CRC SEP)
•Newly diagnosed after the study start or
•If MS onset occurred before study start, regular follow-up in a CRC SEP
•Irreversible disability ≤ 7.0 (permanent use of a wheelchair) on EDSS at inclusion in the study
•Inability to answer questionnaires
•Pregnant women at the time of inclusion

Related studies

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266 · Multiple Sclerosis, Spinal Cord Injury

RECRUITINGPhase 3

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy

RECRUITINGPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue

RECRUITINGPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490 · Multiple Sclerosis Spasticity

RECRUITINGPhase 3

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019 · Secondary Progressive Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 26, 2024Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment2,842

Start dateJul 2018

Last updatedSep 26, 2024

Condition

Multiple Sclerosis

Locations shown

CHU de Besançon

Besançon

CHU de Bordeaux

Bordeaux

CHU de Caen

Caen

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 26, 2024Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions